AMOEBA (EPA:ALMIB) - AMOEBA: Transfer of Amoéba's shares to the Euronext Growth Paris market

Transparency directive : regulatory news

10/09/2020 08:45

PRESS RELEASE

Transfer of Amoéba's shares to the Euronext Growth Paris market

Chassieu, September 10, 2020, 8:45 am - AMOEBA (FR0011051598) - producer of a
biological biocide capable of eliminating the risk in water and human wounds,
and of a biocontrol product for plant protection, still in the testing phase,
announces the transfer of the listing of its shares from the Euronext Paris
regulated market (compartment C) to the Euronext Growth Paris multilateral
trading facility.

The application for the admission of Amoéba's shares to the Euronext Growth
market in Paris was approved by the Euronext Admissions Committee on September
7, 2020.

As indicated in the company's previous press releases, this transfer will
enable Amoéba to be listed on a market more suited to its size and market
capitalization. It should also simplify the Company's operations and reduce the
costs related to its listing, while allowing it to continue to benefit from the
attractions of the financial markets.

Amoéba will continue to provide accurate, precise and truthful information,
making public any inside information concerning the company, in accordance with
the European Regulation on Market Abuse (MAR Regulation).

The information document prepared in connection with this transfer is available
online on the company's website www.amoeba-biocide.com under the heading
"Investors / Regulatory information and financial documents / other
information".

Amoéba has chosen Portzamparc BNP Paribas as Listing Sponsor to accompany it
on the Euronext Growth Paris market.

The ISIN share identification code remains unchanged (FR0011051598) and the
mnemonic code becomes ALMIB. In addition, the holding of Amoéba shares remains
eligible for PEAs and PEA-SMEs

Definitive timetable for the transfer of listing market

September 10, 2020 before market opening:

- Distribution of a Euronext notice announcing the delisting of the company's
shares from Euronext Paris
- Distribution of a Euronext notice announcing the listing of the company's
shares on Euronext Growth Paris

September 14, 2020 :

- Delisting of Amoéba's shares on Euronext Paris (before market opening)
- Listing of Amoéba's shares on Euronext Growth Paris (at the opening)

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.
(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
General Manager
+33 4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors and Media Relations
Grégory BOSSON / Mathieu CALLEUX
Agence Calyptus
+33(0)1 53 65 37 90
amoeba@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the Universal
Registration Document of AMOEBA filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) on April 30, 2020 under number
D20-0416 (a copy of which is available on www.amoeba-biocide.com). The
forward-looking statements contained in this press release are also subject to
risks not yet known to AMOEBA or not currently considered material by AMOEBA.
The occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of AMOEBA to be materially
different from such forward- looking statements.

AMOEBA's latest news

02/05/2024 18:00

AMOEBA (EPA:ALMIB) - AMOEBA: Transfer of Amoéba's shares to the Euronext Growth Paris market

Transparency directive : regulatory news

AMOEBA's latest news

Other stories